What is Raremark?
Raremark operates at the intersection of health technology and clinical research, specializing in the creation of patient-centric networks for rare disease communities. By utilizing advanced machine learning and behavioral science, the platform facilitates the collection of anonymized, aggregated patient data that is critical for biopharmaceutical companies seeking to expedite clinical trials and improve speed-to-market metrics. The company's core value proposition lies in its ability to increase health literacy and patient retention, effectively transforming individual patient experiences into a scalable, high-value knowledge base. Headquartered in London with a strategic presence in Boston and New York, Raremark is redefining how medical research interacts with the patient experience, ensuring that rare disease insights are no longer siloed but are instead actionable assets for drug developers.
How much funding has Raremark raised?
Raremark has raised a total of $6.9M across 3 funding rounds:
Private Equity
$1M
Series A
$3.8M
Other Financing Round
$2.1M
Private Equity (2016): $1M, investors not publicly disclosed
Series A (2018): $3.8M led by Ananda Ventures, Albion Capital Group, Oltre Venture, and Cass Entrepreneurship Fund
Other Financing Round (2018): $2.1M, investors not publicly disclosed
Key Investors in Raremark
Albion Capital Group
Albion Capital Group is a prominent venture capital firm that focuses on long-term partnerships with high-growth companies, particularly in the technology and healthcare sectors.
Cass Entrepreneurship Fund
The Cass Entrepreneurship Fund is a venture capital entity based at Cass Business School that provides equity financing to high-potential, revenue-generating businesses.
Ananda Ventures
Ananda Ventures is an investment firm known for supporting impact-driven enterprises that demonstrate significant potential for social and commercial scalability.
What's next for Raremark?
With the recent infusion of capital, Raremark is poised to deepen its investment in data analytics and machine learning capabilities to further refine its patient engagement models. The strategic roadmap likely involves expanding its reach within the biopharmaceutical sector, where the demand for high-fidelity, real-world evidence is at an all-time high. By strengthening its research networks, the company aims to solidify its position as an essential partner in the clinical development lifecycle. Future growth will likely focus on scaling its operational infrastructure in the United States and Europe, ensuring that the platform remains the primary conduit for patient-led insights in the rare disease space. As the company continues to mature, its focus will remain on optimizing the intersection of behavioral science and clinical data to drive better health outcomes.
See full Raremark company page
